MET Y1003N

CI-VAR-00004738Explore in graph →CIViC 4525

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR Exon 19 Deletion AND MET Y1003N	Capmatinib + OsimertinibCombination	Predictive	C	Supports Sensitivity Response	2	submitted	EID11418 A 65-year old female diagnosed with lung adenocarcinoma revealed several brain lesions, the largest measuring 1.8 x 1.5 x 1.9 cm. COBAS EGFR mutation test was run and revealed EGFR exon 19 deletion mu… (full text at CIViC) PMID 36188633 · Wilgucki et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.